Hexedrone

Hexedrone (alpha-methylaminohexanophenone, N-methyl-nor-hexedrone) is a synthetic stimulant of the cathinone chemical class, structurally related to pentedrone and A-PHP. It is the hexanophenone member of the alpha-keto-amphetamine (cathinone) family — differing from pentedrone by the addition of a single carbon in the ketone chain — and represents a typical structural modification within the series of cathinone-class stimulants that proliferated in the NPS market in the 2010s.

Hexedrone's pharmacological mechanism is believed, based on structural analogy, to involve dopamine and norepinephrine reuptake inhibition, consistent with other simple (non-pyrrolidine, non-methylenedioxy) cathinones of its type. This NDRI profile produces predominantly stimulant effects — increased energy, focus, mild euphoria, cardiovascular activation, and appetite suppression — without significant entactogenic component. The subjective effects are described as similar to pentedrone and other cathinone stimulants of this structural type, with some community characterization as a moderate-potency cathinone.

Hexedrone is among the less extensively documented cathinones, with limited community reporting and very sparse formal pharmacological characterization. The small number of available community accounts suggest it occupies a mid-range position in the cathinone potency/compulsive-use spectrum, with the expected cathinone stimulant risk profile but without the extreme compulsive liability associated with pyrrolidine cathinones like A-PVP or MDPV.

Like all insufficiently characterized NPS, hexedrone presents an inherent uncertainty risk: the absence of formal safety data means that the full toxicological profile — including chronic effects, drug interactions, and neurotoxic potential — remains unknown.